CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
Active, not recruiting · NCT06449586 · Registry updated 2025-12-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2025-12-15 | NCT06449586 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ruijin Hospital | 454 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ruijin Hospital of Shanghai Jiaotong University | Shanghai | China | 4 |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai | China | 21 |
| Shanghai Liquan Hospital | Shanghai | China | 4 |
| The First Hospital of Zhejiang University School of Medicine | Hangzhou | China | 2 |
| Tongji Hospital of Huazhong University of Science and Technology, Wuhan | Wuhan | China | 2 |